Intiflo 0.75mg/ml Infusion
Marketer
Cipla Ltd
Salt Composition
Eptifibatide (0.75mg/ml)
Overview Intiflo 0.75mg/ml Infusion
CardioFlo 0.75mg/ml infusion is an anticoagulant preventing the development of dangerous blood clots. It's indicated for heart attack treatment and to hinder clot formation during cardiac angioplasty (a procedure enhancing coronary blood flow). Administration of CardioFlo 0.75mg/ml infusion requires physician oversight; dosage and treatment length are determined individually. Continue all other prescribed medications, even after this injection, as directed. Potential side effects include thrombocytopenia, increasing bleeding risk. Report immediately any petechiae or blood in your emesis, urine, or feces. Hypotension is another possible adverse reaction. Your physician will discuss the advantages and potential risks prior to administration. Use is contraindicated or requires caution in certain patients. Disclose any bleeding disorders, hepatic or renal impairment, pregnancy, breastfeeding, or concurrent medications before commencing treatment.
Primary Ingredients of Intiflo 0.75mg/ml Infusion
No text provided. Please provide the text you wish me to rephrase.
Uses of Intiflo 0.75mg/ml Infusion
Thrombosis prophylaxis | Myocardial infarction prevention
Major Benefits of Intiflo 0.75mg/ml Infusion:
This medication will be administered by your healthcare provider; self-medication is strictly prohibited.
Common Side effects of Intiflo 0.75mg/ml Infusion:
- Bleeding
- Decreased blood pressure
How to use Intiflo 0.75mg/ml Infusion:
This medication will be administered by your healthcare provider; self-medication is strictly prohibited.
How Intiflo 0.75mg/ml Infusion works:
Intiflo 0.75mg/ml infusion is an antithrombotic agent that inhibits platelet aggregation, reducing the risk of dangerous thrombus development.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
Alcohol consumption alongside Intiflo 0.75mg/ml Infusion may pose safety risks; physician consultation is advised.
PregnancySAFE IF PRESCRIBED
Pregnancy use of Intiflo 0.75mg/ml Infusion is typically deemed safe. Preclinical trials in animals revealed minimal or no harm to offspring; nevertheless, clinical data from human trials remain scarce.
Breast feedingCAUTION
Administering Intiflo 0.75mg/ml Infusion to breastfeeding mothers requires careful consideration. Lactation should be temporarily suspended throughout the mother's treatment and until the medication is fully cleared from her system.
DrivingNOT RELEVANT
Intiflo 0.75mg/ml Infusion is exclusively administered in a hospital setting.
KidneyCAUTION
Administering Intiflo 0.75mg/ml Infusion requires careful consideration in individuals with impaired renal function. A modified Intiflo 0.75mg/ml Infusion dosage might be necessary. Physician consultation is advised. Intiflo 0.75mg/ml Infusion is contraindicated for patients exhibiting severe kidney disease.
LiverCONSULT YOUR DOCTOR
Data regarding Intiflo 0.75mg/ml Infusion use in patients exhibiting hepatic impairment is scarce. Physician consultation is advised. Intiflo 0.75mg/ml Infusion is contraindicated for patients with advanced liver disease.
What if you forget to take Intiflo 0.75mg/ml Infusion :
Omit a scheduled Intiflo 0.75mg/ml Infusion? Seek your physician's advice.
Facts to Know About Intiflo 0.75mg/ml Infusion
| Label | Value |
|---|---|
| Chemical Type | Peptide and Amino Acid Analogs |
| Developing Habits | No. |
| Treatment Category | KINSHIP |
| Action Class | IIb/IIIa receptor antagonists |
3,018 People bought this recently